Vivos Therapeutics Announces 2021 Annual Breathing Wellness Conference Presented by The Vivos Institute
Vivos Therapeutics (NASDAQ: VVOS) has announced the 3rd-annual Breathing Wellness Conference, set for October 20-23, 2021, in Las Vegas. The event aims to educate dentists and doctors about innovative treatments for patients suffering from obstructive sleep apnea (OSA) and snoring. Key speakers will discuss the implications of OSA on chronic health issues like heart disease and the latest advancements in dentofacial sleep medicine. Vivos strives to provide non-invasive solutions, differentiating itself from traditional treatments like CPAP machines.
- Hosting the 3rd-annual Breathing Wellness Conference to increase awareness about OSA.
- Focus on non-invasive treatments for OSA, potentially enhancing patient outcomes.
- Engagement with global dental community through educational sessions with top experts.
- None.
Dentists from around the world to learn about the innovative and life-changing treatments for patients suffering from obstructive sleep apnea and snoring
HIGHLANDS RANCH, Colo., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, today announced the commencement of the 3rd-annual Breathing Wellness Conference presented by The Vivos Institute, which will take place from October 20-23, 2021, at Caesars Palace in Las Vegas, Nevada.
Dentists and medical doctors from around the world will hear from the industry’s top experts on OSA about its impact on chronic conditions such as heart disease, chronic fatigue, and dementia. Attendees will also have the opportunity learn how innovations supporting the science of dentofacial sleep medicine are transforming the future of dentistry forever.
“Dentists are essential to solving the sleep and breathing epidemic as they serve as the front line to proper screening, education, and increasingly, treatment. Our annual Breathing Wellness Conference gives us a chance to educate these individuals on the dangers of OSA and share more about the latest innovations in treatment as we seek to improve the oral and overall health of patients,” said Kirk Huntsman, CEO, Vivos. “Rather than patch OSA with temporary, invasive solutions like CPAP machines and surgery, dentists are leading the change and focusing on potentially life-changing treatments that address the root cause of OSA.”
Dentists and other doctors appearing at the Breathing Wellness Conference as guest speakers include:
- Mimi Guarneri, MD: Sleep-Disordered Breathing: A Reversible Cardiovascular Risk Factor
- Dave Singh, DMD, PhD, DDSc: Introduction to Craniofacial Sleep Medicine
- Ben Miraglia, DDS: How Did We Get Here – Origins of Sleep-Disordered Breathing and Sleep Apnea
- Jon Caulfield, DDS: The Paradigm Shift – Looking Beyond the Mouth
- Jerry Hu, DDS: My Personal Journey
- Kalli Hale, DDS: Don’t Roll the Dice on Your Airway
- Sahil Chopra, MD: Interpreting Home Sleep Tests
- Matthew Walker, PhD: Why Sleep?
- Chris Farrugia, DDS: Medical Billing in the Dental Practice
For more information about the 2021 Annual Breathing Wellness Conference Presented by The Vivos Institute click here: https://thevivosinstitute.com/breathing-wellness-conference-2021/.
About the Vivos Institute
Located in Denver, Colorado, the 15,000-square-foot Vivos Institute was established by Vivos Therapeutics, Inc. to provide advanced post-graduate education and training to dentists, dental teams and other healthcare providers from around the world in a live and hands-on setting. The Institute’s emphasis is on educating healthcare providers about OSA and Vivos’ treatments for OSA within their practice areas, along with training on Vivos’ related practice management tools for dentists.
About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (OSA). The Vivos treatment involves customized oral appliances and treatment protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for adults with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients treated worldwide by more than 1,250 trained dentists.
Combining proprietary technologies and protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology, for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “aim”, “may”, “could”, “expects”, “projects,” “intends”, “plans”, “believes”, “predicts”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the anticipated benefits of the Company’s Breathing Wellness Conference as described herein) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC's website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Vivos Investor Relations Contact:
Edward Loew
Investor Relations Officer
(602) 903-0095
ed@vivoslife.com
Vivos Media Relations Contact:
Joe McIntyre / Jenny Robles
KCSA Strategic Communications
(856) 381-8996 / (212) 896-1231
jmcintyre@kcsa.com / jrobles@kcsa.com
FAQ
What is the Breathing Wellness Conference presented by Vivos?
How does Vivos Therapeutics address obstructive sleep apnea?
What topics will be covered at the Breathing Wellness Conference?
Who are some speakers at the Breathing Wellness Conference?
What innovative solutions does Vivos offer for OSA?
